So speaking to safety first, we found that the safety profile was overall acceptable and the treatment was well tolerated. So there were two grade three toxicities at the time of the actual intervention. And both of these were transient grade 3 toxicities that did not impact radiation or the subsequent resuming of immunotherapy. So one was transient hypotension and then the other one was pleuritic pain after injection to that site...
So speaking to safety first, we found that the safety profile was overall acceptable and the treatment was well tolerated. So there were two grade three toxicities at the time of the actual intervention. And both of these were transient grade 3 toxicities that did not impact radiation or the subsequent resuming of immunotherapy. So one was transient hypotension and then the other one was pleuritic pain after injection to that site. But these had resolved shortly after the injection and did not have anything to do with the actual product itself and then later side effects there was one case of grade 3 skin fibrosis at the site of injection most of the other side effects were all lower grade and the majority of them were attributed to radiation that had resolved on their own and then as far as efficacy goes the overall response rate we saw was 42 percent and we wanted to see if we had different response rates at the site that was injected and radiated and also sites that were not intervened on and so we did see responses for both so for the sites that were injected and radiated, the response rate was about 45%. And then for the non-injected lesions, so-called abscopal responses, we saw about a 30% response rate. So for the non-injected, non-irradiated lesions, very small number. We only had 10 to look at, and then there were three responses so 30% so very small numbers early days but there is an efficacy signal
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.